Everything below concerns Incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
== Scientific contributions == Potassium channels demonstrate a seemingly counterintuitive activity: they permit the passage of potassium ions, whereas they do not allow the passage of the much smaller sodium ions. Before MacKinnon's work, the detailed molecular architecture of potassium channels and the means by which they conduct ions were only generally known and indirectly inferred. In 1998, despite barriers to the structural study of integral membrane proteins that had thwarted most attempts for decades, MacKinnon and colleagues determined the three-dimensional molecular structure of a potassium channel from an actinobacterium, Streptomyces lividans, utilizing X-ray crystallography. With this structure and other biochemical experiments, MacKinnon and colleagues were able to explain the exact mechanism by which potassium channel selectivity occurs. His prize-winning research was conducted primarily at the Cornell High Energy Synchrotron Source (CHESS) of Cornell University, and at the National Synchrotron Light Source (NSLS) of Brookhaven National Laboratory. MacKinnon was elected to the American Philosophical Society in 2005. In 2007 he became a foreign member of the Royal Netherlands Academy of Arts and Sciences.
==== Absorption ==== When taken orally, DMT is metabolized by monoamine oxidase (MAO) enzymes in the liver and gut, and is thus not orally bioavailable unless a monoamine oxidase inhibitor (MAOI) is taken (as is naturally found in the ayahuasca brew). As such, DMT by itself is instead taken by parenteral administration. Closely coextending with peak psychedelic effects, the mean time to reach peak concentration (Tmax) has been determined to be 10 to 15 minutes in whole blood after intramuscular injection, and 2 to 3 minutes after intravenous administration. When taken orally mixed in an ayahuasca decoction or in freeze-dried ayahuasca gel caps, DMT Tmax is considerably delayed to 1.8 hours on average, and 1.5 to 2 hours, respectively. DMT peak level concentrations (Cmax) measured in the blood after intramuscular (IM) injection (0.7 mg/kg, n = 11) and in plasma following intravenous administration (0.4 mg/kg, n = 10) of fully psychedelic doses are in the range of around 14 to 154 μg/L and 32 to 204 μg/L, respectively. The corresponding molar concentrations of DMT are therefore in the range of 0.074–0.818 μmol/L in whole blood and 0.170–1.08 μmol in plasma.
Pyruvate formate-lyase activating enzyme (PFL-AE) catalyzes the activation of PFL, a central enzyme in anaerobic glucose metabolism in microbes. Benzylsuccinate synthase (BSS) is a central enzyme in anaerobic toluene catabolism.
== Laboratory scale == Centrifugal partition chromatography has been extensively used for isolation and purification of natural products for 40 years. Due to the ability to get very high selectivity, and the ability to tolerate samples containing particulated matter, it is possible to work with direct extracts of biomass, opposed to traditional liquid chromatography, where impurities degrade the solid stationary phase so that separation become impossible. There are numerous laboratory scale centrifugal partition chromatography manufacturers around the world, like Gilson (Armen Instrument), Kromaton (Rousselet Robatel), and AECS-QUIKPREP. These instruments operate at flow rates of 1–500 mL/min. with stationary phase retentions of 40–80%. With the new rotor system created after 2022, LiLiChro was able to create a truly analytical instrument (miniLiLi) with a rotor internal volume of only 34ml, which means it can operate at a flow rate of 1ml/min. On the other hand, both the miniLiLi and the 140ml midiLiLi can operate with 90+% stationary phase retention.
Sources: en.wikipedia.org
== Function == Glucagon generally elevates the concentration of glucose in the blood by promoting gluconeogenesis and glycogenolysis. Glucagon also decreases fatty acid synthesis in adipose tissue and the liver, as well as promoting lipolysis in these tissues, which causes them to release fatty acids into circulation where they can be catabolised to generate energy in tissues such as skeletal muscle when required. Glucose is stored in the liver in the form of the polysaccharide glycogen, which is a glucan (a polymer made up of glucose molecules). Liver cells (hepatocytes) have glucagon receptors. When glucagon binds to the glucagon receptors, the liver cells convert the glycogen into individual glucose molecules and release them into the bloodstream, in a process known as glycogenolysis. As these stores become depleted, glucagon then encourages the liver and kidney to synthesize additional glucose by gluconeogenesis. Glucagon turns off glycolysis in the liver, causing glycolytic intermediates to be shuttled to gluconeogenesis. Glucagon also regulates the rate of glucose production through lipolysis. Glucagon induces lipolysis in humans under conditions of insulin suppression (such as diabetes mellitus type 1). Glucagon production appears to be dependent on the central nervous system through pathways yet to be defined. In invertebrate animals, eyestalk removal has been reported to affect glucagon production. Excising the eyestalk in young crayfish produces glucagon-induced hyperglycemia.
Wartime conditions, including German bombing, made progress difficult. The 55-litre (12 imp gal) milk churns needed for shipment were in short supply, and special arrangements were made with the Ministry of Supply. The brew was initially despatched by rail to minimise the use of rationed petrol. The first 680 litres (150 imp gal) of brew, containing 6.1 million units at 9 units per mL, were delivered to Florey on 28 October 1942. Kemball, Bishop & Co. built an extraction plant, which became operational on 24 November 1943. In the meantime, Imperial Chemical Industries (ICI) had established a small production unit at its plant in Blackley and had begun shipments in December 1941. In May 1942, production moved to a purpose-built plant at Trafford Park, which initially produced two million Oxford units of penicillin per week. Production was ramped up to sixty million units per week by the time the plant was closed in March 1944; production shifted thereafter to a new plant that produced 300 million units per week. In 1947 ICI decided to construct a new plant to produce 32,000 litres (7,000 imp gal) of penicillin per day by the deep submergence method. Glaxo Laboratories opened a small production plant at Greenford in December 1942 that produced 70 litres of penicillin broth per week. In February 1943, it opened a second plant at Aylesbury. Initially it used the techniques developed at Oxford, but in September 1943 it switched to using corn steep liquor as a medium, and switched to using the NRRL 1249.B21 strain of mould provided by Coghill.
Ember was an American company based in Boston, Massachusetts, USA, which is now owned by Silicon Labs. Ember had a radio development centre in Cambridge, England, and distributors worldwide. It developed Zigbee wireless networking technology that enabled companies involved in energy technologies to help make buildings and homes smarter, consume less energy, and operate more efficiently. The low-power wireless technology can be embedded into a wide variety of devices to be part of a self-organizing mesh network. All Ember products conform to IEEE 802.15.4-2003 standards. In May 2012, Ember was acquired by Silicon Labs.
== Background == Found in several fungal species such as Fusarium graminearum NRRL 2903 (formerly misidentified as Dactylium dendroides), and other species of Fusarium and Aspergillus genera, galactose oxidase was first isolated in 1959. This enzyme is secreted by fungi to function in extracellular space. Although the oxidation reaction of D-galactose gives galactose oxidase its name, the coupled reduction of dioxygen to hydrogen peroxide is believed to have greater physiological significance in yeasts. Hydrogen peroxide which can be produced by yeasts in this way is possibly a bacteriostatic agent.
In November 1993, sixteen months after Nickell's homicide, single mother Samantha Bisset and her four-year-old daughter Jazmine were murdered in their flat in Plumstead, London. The police detectives investigating the Bisset murders found the preponderance of similarities with the murder of Nickell very notable, and sat down to discuss this with the detectives from the Nickell murder. The Nickell detectives, who already had Stagg in custody at that time and thus had stopped looking for suspects, rejected – with "hostility" – the Bisset detectives' theory that the unknown murderer in the Bisset case was the true perpetrator in the Nickell case. The detective who later arrested Robert Napper for the Bisset murders also found the similarities convincing, and suggested Napper as a suspect in the murder of Rachel Nickell. In 1995, Napper was convicted for the Bisset murders. In July 2006, the Scotland Yard team interviewed him for two days at Broadmoor. Napper, 40 years old at that time, had been diagnosed as having paranoid schizophrenia and Asperger syndrome and had been held at the secure institution for more than ten years. On 28 November 2007, Napper was charged with Nickell's murder. He appeared at City of Westminster Magistrates' Court on 4 December 2007, where he was granted bail on condition he remained at Broadmoor psychiatric hospital until another hearing on 20 December 2007. On 24 January 2008, he pleaded not guilty to Nickell's murder and the trial started on 11 November 2008.
Sources: en.wikipedia.org
Academy players to be nominated by 15 September. With a bidding process held on 24 November along with father–son selections during the national draft. The free agency offer period; held between 9 October and 18 October. Three further free agency periods are held for delisted players, between 31 October and 9 November, 11 November to 20 November, and 25 November to 26 November. The trade period; held between 12 October and 22 October. The 2015 national draft; held on 24 November at the Adelaide Convention Centre, which, for the first time, included live bidding for academy and father-son selections. The 2016 pre-season draft; which was to be held on 27 November, but was cancelled when all clubs declined to take part, and The 2016 rookie draft; which was held on 27 November. Additionally, following the guilty verdicts handed down to 34 past and present Essendon players in January 2016 for doping violations, Essendon was given the opportunity to recruit top-up players between January and March 2016.
Although it may seem like a so-called disappearing polymorph can no longer be produced at all, it is believed that it is always possible in principle to reconstruct the original polymorph in a lab that has not been contaminated by the new morph. This was demonstrated in the ranitidine case. However, doing so is usually impractical or uneconomical. In some cases, the original morph can be reconstructed by a different pathway with different chemical kinetics, as in the case of progesterone. This is of concern to the pharmaceutical industry, where disappearing polymorphs can ruin the effectiveness of their products and make it impossible to manufacture the original product if there is any contamination. There have been cases in which a laboratory that attempted to reproduce crystals of a particular structure instead grew not the original but a new crystal structure. The drug paroxetine was subject to a lawsuit that hinged on such a pair of polymorphs, and multiple life-saving drugs, such as ritonavir, have been recalled due to unexpected polymorphism.
Cresskill is a borough in Bergen County, in the U.S. state of New Jersey. As of the 2020 United States census, the borough's population was 9,155, an increase of 582 (+6.8%) from the 2010 census count of 8,573, which in turn reflected an increase of 827 (+10.7%) from the 7,746 counted in the 2000 census. This borough got its name from "Cress", referring to the watercress that grew in its streams, and "Kill", referring to the stream passing through.
=== Selective serotonin reuptake inhibitors === Selective serotonin reuptake inhibitors (SSRIs) selectively inhibit the reuptake of serotonin and are a widely used group of antidepressants. With increased receptor selectivity compared to TCAs, undesired effects such as poor tolerability are avoided. Serotonin is synthesized from an amino acid called L-tryptophan. Active transport system regulates the uptake of tryptophan across the blood–brain barrier. Serotonergic pathways are classified into two main ways in the brain: the ascending projections from the medial and dorsal raphe and the descending projections from the caudal raphe into the spinal cord.
Alteplase binds to fibrin in a blood clot and activates the clot-bound plasminogen. Alteplase cleaves plasminogen at the site of its Arg561-Val562 peptide bond to form plasmin. Plasmin is a fibrinolytic enzyme that cleaves the cross-links between polymerized fibrin molecules, causing the blood clot to break down and dissolve, a process called fibrinolysis.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.